Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Michael Clayman, M.D., President and Chief Executive Officer, will participate in an analyst-led fireside chat at the Oppenheimer 31st Annual Healthcare Conference
BURLINGTON, Mass., March 15, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics Inc. (Nasdaq:FLXN) announced today that Michael Clayman, M.D., President and Chief Executive Officer, will participate in an analyst-led fireside chat at the Oppenheimer 31st Annual Healthcare Conference. The virtual fireside chat is scheduled to begin at 10:00 a.m. ET on Wednesday, March 17, 2021.
To access the live webcast of the presentation, please visit the Flexion website at http://ir.flexiontherapeutics.com.
About Flexion Therapeutics
Flexion Therapeutics (Nasdaq:FLXN) is a biopharmaceutical company focused on the development and commercialization of novel, local therapies for the treatment of people with musculoskeletal conditions, beginning with osteoarthritis, the most common form of arthritis. The Company’s core values are focus, ingenuity, tenacity, transparency and fun. Please visit flexiontherapeutics.com.
Contact:
Scott Young
Vice President, Corporate Communications & Investor Relations
Flexion Therapeutics, Inc.
T: 781-305-7194
syoung@flexiontherapeutics.com
